“Energy Armageddon Coming to America” and some updates on old favorites

We’ll be skipping almost all publishing next week, including the Friday File, as Stock Gumshoe closes down for a few days for vacation and redesign prep on the new and improved StockGumshoe.com — so I’ll try to make this one good enough to last a couple weeks for you! The new site, in case you’re [...]

What is Frank Curzio’s “$10,000 Pill” Stock?

I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a [...]

“How to Buy Apple for $12 a Share”

Louis Navellier is certainly not shy — he’s sent out several ads telling folks that the recent market turmoil is your opportunity to buy his favorite stocks (he’s a “growth” guy, so his faves are stocks with big revenue growth, earnings growth, momentum and upside surprises). I thought that might be a nice antidote — [...]

“Rogue MIT Scientists’ Billion-Dollar Energy Cure”

These are the kind of teaser ads that always bring a smile to my face — top secret technology from “rogue” scientists, unknown breakthroughs that will change the face of the world and make us rich, that’s what teaser-land is all about! And certainly Nick Hodge knows that — all the publishers use the same [...]

“10 Best Stocks to Hold Forever” (part one)

Paul Tracy of StreetAuthority has been touting a special report he’s selling called “10 Best Stocks to Hold Forever” — he uses the example of the March 2009 market bottom as a great time to buy dominant, dividend-paying multinational companies … … and says that the recent market weakness again points at the opportunity provided [...]

“When the China Bubble Bursts: 6 Investments to Give You Profits PLUS Protection Through the Coming Crisis”

Today’s teasers come in from Mark Skousen, who edits the Forecasts & Strategies newsletter and has graced our pages a few times in the past — most recently when he touted Cubist Pharmaceuticals very aggressively as a “winning lottery ticket” and “superbug killer” (that one did quite well, thanks to both the FDA and a [...]